Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Commodore Capital and related filers report a significant passive stake in Alto Neuroscience, Inc. They filed an amended Schedule 13G/A showing beneficial ownership of 3,245,628 shares of common stock, representing 9.9% of the class as of December 31, 2025.
The position consists of 1,823,196 Alto Neuroscience shares and 1,422,432 additional shares that each filer may acquire through exercising a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The calculation uses 31,066,335 shares outstanding as of November 7, 2025 plus the warrant shares. The filers certify the securities are not held to change or influence control of Alto Neuroscience.
Vestal Point Capital reports beneficial ownership of 2,485,000 shares of Alto Neuroscience common stock, representing 8% of the class. The shares are held through the Vestal Point fund and a managed account, with voting and dispositive power shared between Vestal Point Capital and Ryan Wilder.
The ownership percentage is based on 31,066,335 shares of Alto Neuroscience common stock outstanding as of November 7, 2025. The securities are certified as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Alto Neuroscience.
Perceptive Advisors and affiliates report a 9.99% stake in Alto Neuroscience, Inc. They beneficially own 3,249,934 shares of common stock, including shares issuable under pre-funded warrants, based on 31,066,335 Alto shares outstanding as of November 7, 2025.
The Master Fund directly holds 1,784,393 Alto common shares and 2,536,354 pre-funded warrants exercisable at $0.0001 per share, subject to a 9.99% beneficial ownership cap. Perceptive Advisors acts as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
The reporting persons certify the securities were not acquired and are not held to change or influence control of Alto Neuroscience, other than activities solely connected with a nomination under Rule 14a-11.
Alto Neuroscience reported that President and CEO Etkin Amit received an employee stock option grant on February 11, 2026. The option covers 306,000 shares of common stock at an exercise price of $16.71 per share and expires on February 10, 2036.
According to the vesting terms, 25% of the shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service. After this award, Amit directly holds options for 306,000 shares.
Alto Neuroscience Chief Medical Officer Adam Savitz received a grant of 124,000 employee stock options on February 11, 2026. The options have an exercise price of $16.71 per share and expire on February 10, 2036. They relate to Alto Neuroscience common stock.
According to the vesting terms, 25% of the shares underlying the option will vest on February 11, 2027. The remaining shares will then vest in equal monthly installments over the following three years, provided Savitz continues in service through each vesting date. After this grant, he directly holds 124,000 derivative securities in the form of these options.
Smith Nicholas Conrad reported acquisition or exercise transactions in a Form 4 filing for ANRO. The filing lists transactions totaling 200,000 shares. Following the reported transactions, holdings were 200,000 shares.
Alto Neuroscience reported that its Chief Operating Officer, Michael Conick Hanley Jr., received an employee stock option grant. On February 11, 2026, he was awarded options to acquire 131,000 shares of common stock at an exercise price of $16.71 per share.
The options vest over four years: 25% of the underlying shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service with the company.
Alto Neuroscience, Inc. disclosed that one of its directors received a new stock option grant. On 01/02/2026, the director was granted an option to purchase 5,243 shares of Alto Neuroscience common stock at an exercise price of $16.59 per share, expiring on 01/01/2036.
The option vests in four equal quarterly installments during 2026: 1,311 shares on March 31, 1,311 shares on June 30, 1,310 shares on September 30, and 1,311 shares on December 31, subject to the director’s continuous service. The filing notes that this option was issued under the company’s Non-Employee Director Compensation Policy in lieu of $62,000 in cash retainer fees.
Alto Neuroscience director reports new stock option grant. A board member of Alto Neuroscience, Inc. filed a Form 4 reporting receipt of a stock option covering 7,189 shares of common stock on 01/02/2026.
The option was granted under the company’s Non-Employee Director Compensation Policy in lieu of cash retainer fees of $85,000. Vesting is scheduled in four installments during 2026: 1,797 shares on March 31, 1,797 shares on June 30, 1,798 shares on September 30, and 1,797 shares on December 31, contingent on the director’s continuous service through each vesting date.
Alto Neuroscience, Inc. director compensation is disclosed through a new stock option grant. On 01/02/2026, a reporting person serving as a director received an employee stock option to buy 4,228 shares of common stock at an exercise price of $16.59 per share. The option relates to 4,228 underlying common shares and was granted under the company’s Non-Employee Director Compensation Policy in lieu of $50,000 in cash retainer fees. The option vests in four equal installments of 1,057 shares on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, if the director’s service continues through each vesting date.